Protalix Biotherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease

CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase (GCD) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans.

MORE ON THIS TOPIC